have just gone through the presentation recording, and further confirmed my view from late January that OmniCAR and CellPryme are duds from the perspective of commercialisation and forming partnerships. however this's not saying that they're of no value, they are, and will benefit PTX themselves if they succeed in taking PTX-100/200 or any other target therapies they may come up with through to success.
as Steven put it, from the angle of a deal seeker, in the past 12 months the response from potential partners have been quite underwhelming, that "everyone's looking after their own patches now". and I frankly think those potential partners were just being polite, and would only give proper feedbacks rather than the hard truth. they can keep these two platforms active, however shouldn't allocate too much resource and marketing focus moving forward.
I'm quite positive though, round up the market cap to 80m, and I believe PTX-100 alone would worth it, and Steven were apparently quite excited about the progress, and we may have the read out soon. I do hope they don't discount on PTX-200, it's been good so far and they should carry on.
I maintain my view of a Lower Limit of 8c for near term share price fluctuation, and will wait there.
have a good weekend all, time for the club and beers.
PTX Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
